Form 4: AN2 Therapeutics Director and 10% Owner Sells 200,000 Shares

Braden Michael Leonard, a Director and 10% owner of AN2 Therapeutics, Inc. (ANTX), reported the sale of 200,000 shares of common stock at $1.09 per share.

Summary

• Braden Michael Leonard, identified as both a Director and a 10% owner of AN2 Therapeutics, Inc. (ANTX), filed a Form 4 with the SEC.
• The filing details the disposition of 200,000 shares of ANTX common stock on May 28, 2025.
• These shares were sold at a price of $1.09 per share.
• Following this transaction, Mr. Leonard beneficially owns 3,017,432 shares indirectly.
• The indirect ownership is through BML Investment Partners, L.P., where BML Capital Management, LLC serves as the general partner, and Mr. Leonard is the managing member, exercising investment and voting control.
• Mr. Leonard disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein.

Sentiment

Score: 3

Explanation: The sale of a significant number of shares by a director and 10% owner is generally perceived as a negative signal, suggesting a lack of confidence or a belief that the stock is overvalued. While personal liquidity needs could be a factor, without further context, the market typically views such insider selling unfavorably.

Negatives

• An insider (Director and 10% owner) sold a significant block of 200,000 shares of common stock.
• The sale occurred at a price of $1.09 per share.

Risks

• Insider selling, especially by a director and significant shareholder, can be interpreted by the market as a lack of confidence in the company's future prospects or current valuation.
• The disclosure of this insider sale may lead to negative market sentiment and potential downward pressure on the company's stock price.

Future Outlook

This SEC Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• "Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."

Industry Context

This document reports an insider transaction, which is a company-specific event and does not directly provide context on broader industry trends or competitor activities. However, such transactions are often scrutinized by investors within the industry for signals about company health or valuation.

Stakeholder Impact

• Shareholders: May interpret the insider sale negatively, potentially leading to a decrease in share price due to perceived lack of confidence from a key insider.

Key Dates

Recommendation

Keywords

AN2 Therapeutics, ANTX, SEC Form 4, Insider Trading, Stock Sale, Beneficial Ownership, Braden Michael Leonard, Director, 10% Owner, Equity Securities